Enhancement of the lymphatic system following intravenous administration of ferumoxytol
Pediatric Radiology · 2024
DOI: 10.1007/s00247-024-06061-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Radiology, 2024. Verfasst von Daniel F Young und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Children's Medical Center Dallas, 1935 Medical District Dr, Dallas, TX, 75235, USA. danyou@childrens.com. Hauptthemen laut MEDLINE: Contrast Media, Ferrosoferric Oxide, Heart Defects, Congenital. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Lymphatic imaging is becoming increasingly important in the management of patients with congenital heart disease. However, the influence of the intravenous contrast agent ferumoxytol on lymphatic imaging is not well understood. OBJECTIVE: To evaluate the impact of intravenous ferumoxytol on T1-weighted and T2-weighted lymphatic imaging in patients with congenital heart disease. MATERIALS AND METHODS: We included consecutive patients receiving ferumoxytol-enhanced 3D angiography for congenital heart disease evaluation. The visibility of the thoracic duct was reviewed on the T1-weighted 3D inversion recovery balanced-steady-state free precession (SSFP) with respiratory navigator gating sequence which is routinely used for angiography and the heavily T2-weighted turbo spin echo sequence which is employed for lymphatic imaging. Data on demographics and time interval between contrast administration and imaging were collected. Statistical analyses were performed using t-tests for continuous variables and chi-squared tests for categorical variables. RESULTS: One hundred nineteen consecutive patients with a mean age of 12.46 years±7.7 years were included. Of these, 45 cases underwent both T1-weighted and T2-weighted imaging; the other 74 underwent only T1-weighted imaging. Of the 45 patients, 20 had thoracic duct enhancement on T1-weighted imaging; among the 26 sedated, only 2 showed enhancement, while 18 of 19 non-sedated patients showed enhancement (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Children's Medical Center Dallas, 1935 Medical District Dr, Dallas, TX, 75235, USA. danyou@childrens.com.
- Department of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA. danyou@childrens.com.
- Department of Pediatrics, Children's Medical Center Dallas, 1935 Medical District Dr, Dallas, TX, 75235, USA.
- Department of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
ORCID-Profile: Daniel F Young
Zitieren
APA
Young, D. F., Reddy, S. V., Divekar, A., Vamsee, R., Pimpalwar, S., Hussain, T., & Greer, J. S. (2024). Enhancement of the lymphatic system following intravenous administration of ferumoxytol. Pediatric Radiology. https://doi.org/10.1007/s00247-024-06061-w
Vancouver
Young DF, Reddy SV, Divekar A, Vamsee R, Pimpalwar S, Hussain T, et al. Enhancement of the lymphatic system following intravenous administration of ferumoxytol. Pediatric Radiology. 2024. doi:10.1007/s00247-024-06061-w
BibTeX
@article{Young2024,
author = {Young, Daniel F and Reddy, Surendranath Veeram and Divekar, Abhay and Vamsee, Ravi and Pimpalwar, Sheena and Hussain, Tarique and Greer, Joshua S},
title = {Enhancement of the lymphatic system following intravenous administration of ferumoxytol},
journal = {Pediatric Radiology},
year = {2024},
doi = {10.1007/s00247-024-06061-w}
}
EUVIMED